23 Sep 2019 – Directorate change

Destiny Pharma plc
(“Destiny Pharma” or “the Company”)

Directorate change

Brighton, United Kingdom – 23 September 2019 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs to address the global crisis caused by antimicrobial resistance (AMR), today announces that after 18 years on the Board, Joe Eagle a Non-Executive Director,  has decided to step down from the Board with effect from today. Joe was instrumental in the financing and strategic direction of Destiny as a private company and brought both pharmaceutical and marketing expertise to the development of the lead candidate, XF-73 for the prevention of post-surgical infections. A search for a replacement is underway.

Nick Rodgers, Chairman of Destiny Pharma, commented:

“On behalf of Destiny Pharma, I would like to thank Joe for his considerable contribution to the Company throughout its development as a private company and the transition onto the AIM market. Joe’s understanding of the pharma market and company development has been of great value to Destiny and I am sorry to see him go. We wish him all the very best for the future” .

Joe Eagle, Non-Executive Director, commented:

“I continue to believe that Destiny Pharma, through its XF platform, will develop unique and life-saving antimicrobials to counter the worldwide threat of antimicrobial resistance. I have seen the development of the Company from a small private enterprise to a successful, asset rich public company and wish all the members of the company every success with their future endeavours. It has been a privilege to work with you all.”

For further information, please contact:

Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440

FTI Consulting
Simon Conway / Victoria Foster Mitchell
+44 (0) 20 3727 1000

finnCap Ltd (Nominated Advisor Joint Broker)
Geoff Nash /Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0)20 7220 0500

WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0) 203 705 9330

About Destiny Pharma

Destiny Pharma is an established, clinical stage, innovative biotechnology company focused on the development of novel medicines from its XF Platform that represent a new approach to the treatment of infectious disease. The company’s lead programme is undergoing a Phase 2b clinical trial and is targeting the prevention of post-surgical hospital infections including MRSA. The XF drug candidates are being developed for the prevention and treatment of life-threatening infections caused by antibiotic‑resistant bacteria, often referred to as “superbugs”. Tackling anti-microbial resistance has become a global imperative recognised by the World Health Organisation (WHO) and the United Nations, as well as the G7 and the G20 countries. For further information, please visit https://www.destinypharma.com